首页> 外文OA文献 >Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma
【2h】

Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma

机译:转移性肾细胞癌中全身炎症反应动态变化的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ABSTRACT Purpose: To elucidate the prognostic value of systemic inflammatory response in patients with metastatic renal cell carcinoma (mRCC) who are treated with sunitinib, we evaluated the prognostic role of C-reactive protein (CRP) kinetics. This study also compared prognostic models containing CRP kinetics and neutrophil-to-lymphocyte ratio (NLR) kinetics. Materials and Methods: A consecutive cohort of 94 patients with mRCC who were treated with sunitinib was retrospectively included from Fudan University Shanghai Cancer Center. According to dynamic changes in CRP and the NLR, patients were divided into three groups for analysis of CRP and NLR kinetics. The associations between survival and potential prognostic factors were assessed. The incremental value of prognostication was evaluated. Results: A significant difference (P<0.001) in overall survival (OS) was observed among the three groups of CRP kinetics. The median OS of the non-elevated group was nearly 1.3-fold longer than that of the normalized group (33.0 vs. 26.3 months), and two times longer than that of the non-normalized group (33.0 vs. 14.0 months). Multivariate analysis showed that CRP and NLR kinetics were independent prognostic indicators. The model containing CRP kinetics had a better predictive accuracy than that with NLR kinetics, which was supported by the C-index (0.731 vs. 0.684) and the likelihood ratio χ2 test (79.9% vs. 44.9%). Conclusion: Our study suggests that dynamic changes in CRP can better predict survival in patients with mRCC who are treated with sunitinib. Routine assessment of CRP before and after targeted therapy would help identify patients at risk of a poor outcome.
机译:摘要目的:阐明瑞尼尼治疗的转移性肾细胞癌(MRCC)患者的全身炎症反应的预后价值,我们评估了C-反应蛋白(CRP)动力学的预后作用。该研究还比较了含有CRP动力学和中性粒细胞对淋巴细胞比(NLR)动力学的预后模型。材料和方法:追溯包括孙尼替尼治疗的94例MRCC患者的连续队列,由复旦大学上海癌症中心提供。根据CRP和NLR的动态变化,患者分为三组,用于分析CRP和NLR动力学。评估存活和潜在预后因子之间的关联。评估预后的增量值。结果:在三组CRP动力学中,观察到总存活(OS)的显着差异(P <0.001)。非升高组的中位OS比标准化组(33.0与26.3个月)更长的1.3倍,比非规范化组的两倍长(33.0与14.0个月)。多变量分析表明,CRP和NLR动力学是独立的预后指标。含CRP动力学的模型具有比具有NLR动力学的预测精度更好,由C折射率(0.731对0.684)和可能性比χ2检验(79.9%vs.4.9%)负载。结论:我们的研究表明,CRP的动态变化可以更好地预测与孙尼替尼治疗的MRCC患者的存活。在有针对性治疗之前和之后CRP的常规评估有助于识别患者的患者的危险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号